Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 5/2019

Open Access 01-05-2019 | Case Report

Insulin pump settings and glucose patterns during a 1008-km non-stop bicycle race in a patient with type 1 diabetes mellitus

Authors: Tomasz Klupa, Jerzy Hohendorff, Teresa Benbenek-Klupa, Bartłomiej Matejko, Maciej T. Malecki

Published in: Acta Diabetologica | Issue 5/2019

Login to get access

Excerpt

There is a general consensus that physical activity should be recommended for individuals with type 1 diabetes mellitus (T1DM) [1]. While moderate exercise can be relatively easily managed with respect to diabetes, extreme or prolonged sport activity still remains a challenge [1]. Extreme sports are in general not recommended for individuals with T1DM, but more and more patients choose them. In such cases, diabetes management should be highly individualized, and advanced technologies often can be useful [1]. …
Literature
1.
Riddell MC, Gallen IW, Smart CE et al (2017) Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol 5(5):377–390CrossRef
2.
Matejko B, Benbenek-Klupa T, Malecki MT, Klupa T (2017) Personal insulin pump with predictive low glucose management technology at high altitude. J Diabetes Sci Technol 11(1):176–177CrossRef
3.
Gawrecki A, Matejko B, Benbenek-Klupa T, Wróbel M, Hohendorff J, Klupa T (2016) Type 1 diabetes mellitus at very high altitude. The summit of Mount Damāvand (5670 m) safely reached by 18 patients with type 1 diabetes mellitus. Pol Arch Med Wewn 126(7–8):576–578PubMed
4.
Choudhary P, Olsen BS, Conget I et al (2016) Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 18:288–291CrossRef
5.
Biester T, Kordonouri O, Holder M et al (2017) “Let the algorithm do the work”: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension (SmartGuard) in pediatric type 1 diabetes patients. Diabetes Technol Ther 19(3):173–182CrossRef
Metadata
Title
Insulin pump settings and glucose patterns during a 1008-km non-stop bicycle race in a patient with type 1 diabetes mellitus
Authors
Tomasz Klupa
Jerzy Hohendorff
Teresa Benbenek-Klupa
Bartłomiej Matejko
Maciej T. Malecki
Publication date
01-05-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1254-4

Other articles of this Issue 5/2019

Acta Diabetologica 5/2019 Go to the issue

Letter to the Editor

Diagnosis of cardiovascular autonomic neuropathy in diabetes: as simple as possible, but not simpler?

Short Communication

Risk factor control and outpatient attendance in young adults with diabetes

Editorial

Our second genome and the impact on metabolic disorders: why gut microbiome is an important player in diabetes and associated abnormalities

Letter to the Editor

Diagnosis of cardiovascular autonomic neuropathy in diabetes: as simple as possible, but not simpler? An answer

Original Article

Combination therapy of an iNKT cell ligand and CD40–CD154 blockade establishes islet allograft acceptance in nonmyeloablative bone marrow transplant recipients

Original Article

Glutamate interactions with obesity, insulin resistance, cognition and gut microbiota composition
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits